Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized, double-blind, placebo-controlled study of HMI-115 in women with moderate to severe endometriosis-associated pain
CTR20230517Phase 2Completed
- Sponsor
- HopeMed
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in endometriosis comparing HMI-115 with Placebo (2 arms). Primary endpoint: Change in dysmenorrhea pain at 12 weeks. Started May 2023; status: completed.
02
Drugs
HMI-115
03
Conditions
endometriosis
Beyond the preview
Go deeper on CTR20230517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230517.